Yarrow Bioscience (NASDAQ:YARW) Stock Short Interest Jumps 123.9%

Yarrow Bioscience (NASDAQ:YARW) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 126,528 shares, a growth of 123.9% from the August 31st total of 56,499 shares. Based on an average trading volume of 170,937 shares, the days-to-cover ratio is currently 0.7 days. Currently, 4.9% of the shares of the company are short sold.

Hedge Funds Weigh In On Yarrow Bioscience

Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Yarrow Bioscience during the second quarter valued at $29,000. Two Sigma Securities LLC purchased a new stake in Yarrow Bioscience during the 2nd quarter worth about $26,000. GSA Capital Partners LLP purchased a new stake in Yarrow Bioscience during the 2nd quarter worth about $47,000. T3 Companies LLC acquired a new position in Yarrow Bioscience in the 4th quarter valued at about $548,000. Finally, Nantahala Capital Management LLC acquired a new position in Yarrow Bioscience in the 2nd quarter valued at about $1,301,400,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

Yarrow Bioscience Trading Up 0.8%

NASDAQ:YARW traded up $0.20 during mid-day trading on Tuesday, hitting $24.20. 51,986 shares of the company’s stock traded hands, compared to its average volume of 30,548. The business has a 50 day simple moving average of $33.87. Yarrow Bioscience has a 1 year low of $16.00 and a 1 year high of $46.95. The stock has a market capitalization of $64.61 million, a P/E ratio of -1.65 and a beta of 2.01.

Yarrow Bioscience (NASDAQ:YARW) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($3.33). The business had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.20 million. Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 84.40%.

Yarrow Bioscience Dividend Announcement

The business also recently announced a special dividend, which was paid on Thursday, July 23rd. Investors of record on Wednesday, July 22nd were paid a $19.00 dividend.

Analysts Set New Price Targets

YARW has been the topic of a number of recent research reports. TD Cowen began coverage on Yarrow Bioscience in a report on Tuesday, July 28th. They issued a “buy” rating on the stock. BTIG Research started coverage on Yarrow Bioscience in a report on Monday, August 3rd. They set a “buy” rating and a $58.00 price target for the company. Finally, Wall Street Zen upgraded shares of Yarrow Bioscience to a “hold” rating in a research report on Saturday, August 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $58.00.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.